1219086-87-9

Usage

Uses

Used in Chemical Synthesis:
(Z)-3-(3-Chloro-2-fluorophenyl)-2-(4-chloro-2-fluorophenyl)-2-propenenitrile is used as an intermediate in chemical synthesis for the production of various organic compounds. Its reactive nitrile group and the presence of electron-withdrawing chloro and fluoro substituents on the aromatic rings make it a versatile building block for the synthesis of complex molecules.
Used in Pharmaceuticals:
In the pharmaceutical industry, (Z)-3-(3-Chloro-2-fluorophenyl)-2-(4-chloro-2-fluorophenyl)-2-propenenitrile is used as a key component in the development of new drugs. Its unique structure and reactivity can be exploited to design and synthesize novel pharmaceutical agents with potential therapeutic applications.
Used in Materials Science:
(Z)-3-(3-Chloro-2-fluorophenyl)-2-(4-chloro-2-fluorophenyl)-2-propenenitrile is also utilized in materials science for the development of advanced materials with specific properties. (Z)-3-(3-Chloro-2-fluorophenyl)-2-(4-chloro-2-fluorophenyl)-2-propenenitrile's structural features and reactivity can be harnessed to create materials with tailored characteristics, such as improved thermal stability, mechanical strength, or electrical conductivity, for use in various applications.

Upstream product

• 75279-53-7 2-(4-chloro-2-fluoro-phenyl)acetonitrile 
• 85070-48-0 2-fluoro-3-chlorobenzaldehyde 

Downstream Products

• 1290097-24-3 rac-(2S,3R,4S)-4-(3-chloro-2-fluorophenyl)-3-(4-chloro-2-fluorophenyl)-3-cyano-2-(2,2-dimethylpropyl)pyrrolidine-1-carboxylic acid ((S)-3,4-dihydroxybutyl)amide 
• 1364614-53-8 rac-(6S,7R,8S,8aR)-8-(3-chloro-2-fluoro-phenyl)-7-(4-chloro-2-fluoro-phenyl)-2-((S)-3,4-dihydroxy-butyl)-6-(2,2-dimethyl-propyl)-1-oxo-octahydro-pyrrolo[1,2-a]pyrazine-7-carbonitrile 
• 1364616-38-5 (6R,7S,8R,8aS)-8-(3-chloro-2-fluorophenyl)-7-(4-chloro-2-fluorophenyl)-2-((S)-3,4-dihydroxybutyl)-6-(2,2-dimethylpropyl)-1-oxo-octahydropyrrolo[1,2-a]pyrazine-7-carbonitrile 
• 1219086-88-0 racemic (2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-( 4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)pyrrolidine-2-carboxylic acid tert-butyl ester 
• 1229705-08-1 6-{[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)pyrrolidine-2-carbonyl]amino}naphthalene-2-carboxylic acid 
• 1229703-86-9 4-{[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)pyrrolidine-2-carbonyl]amino}-2-methoxybenzoic acid 
• 1229704-95-3 4-{[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)pyrrolidine-2-carbonyl]amino}-2-fluorobenzoic acid 

Relevant academic research and scientific papers

Practical Synthesis of MDM2 Antagonist RG7388. Part 2: Development of the Cu(I) Catalyzed [3 + 2] Asymmetric Cycloaddition Process for the Manufacture of Idasanutlin

A concise catalytic asymmetric synthesis of idasanutlin (1) was developed in which the key pyrrolidine core, containing four contiguous stereocenters, was constructed via a Ag/MeOBIPHEP promoted [3 + 2] cycloaddition reaction. Further development of the [

Photoactivation of MDM2 Inhibitors: Controlling Protein-Protein Interaction with Light

Selectivity remains a major challenge in anticancer therapy, which potentially can be overcome by local activation of a cytotoxic drug. Such triggered activation can be obtained through modification of a drug with a photoremovable protecting group (PPG), and subsequent irradiation in the chosen place and time. Herein, the design, synthesis and biological evaluation is described of a photoactivatable MDM2 inhibitor, PPG-idasanutlin, which exerts no functional effect on cellular outgrowth, but allows for the selective, noninvasive activation of antitumor properties upon irradiation visible light, demonstrating activation with micrometer, single cell precision. The generality of this method has been demonstrated by growth inhibition of multiple cancer cell lines showing p53 stabilization and subsequent growth inhibition effects upon irradiation. Light activation to regulate protein-protein interactions between MDM2 and p53 offers exciting opportunities to control a multitude of biological processes and has the potential to circumvent common selectivity issues in antitumor drug development.

MDM2 DEGRADERS AND USES THEREOF

The present invention relates to compounds and methods useful for the modulation of mouse double minute 2 homolog ("MDM2") protein via ubiquitination and/or degradation by compounds according to the present invention.

PHOTORESPONSIVE NUTLIN DERIVATIVES AND USES THEREOF

The invention relates to the field of medicine and medicinal chemistry, more in particular to the design, manufacture and use of anti-cancer drugs that can be activated by an external stimulus that can be applied in a spatiotemporal fashion. Provided herein is a compound having the chemical structure or a pharmaceutically acceptable salt thereof.

MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE

The present disclosure relates to bifunctional compounds, which find utility as modulators of Kirsten rat sarcoma protein (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation, accumulation, and/or overactivation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

ASYMMETRIC SYNTHESIS OF A SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDE

The present invention provides an improved method for the large scale production of the compound 4-{[(2R,3S,4R,5S)-3-(3-chloro-2-fluoro-phenyl)-4-(4-chloro-2-fluoro-phenyl)-4-cyano-5-(2,2-dimethyl-propyl)-pyrrolidine-2-carbonyl]-amino}-3-methoxy-benzoic a

Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development

Restoration of p53 activity by inhibition of the p53-MDM2 interaction has been considered an attractive approach for cancer treatment. However, the hydrophobic protein-protein interaction surface represents a significant challenge for the development of s

SUBSTITUTED HEXAHYDROPYRROLO[1,2-C]IMIDAZOLONES

There are provided compounds of formula I or a pharmaceutically acceptable salt thereof, wherein X, Y, R1, R1′, R2, R2′, R3, R4, R5 are as defined herein. The compounds exhibit a

N-SUBSTITUTED PYRROLIDINES

Compounds of formula and enantiomers and pharmaceutically acceptable salts thereof are described, as well as the pharmaceutical compositions containing said compounds and their pharmaceutically acceptable salts, and the use of said compounds and pharmaceu

NOVEL N-SUBSTITUTED-PYRROLIDINES AS INHIBITORS OF MDM2-P-53 INTERACTIONS

There are provided compounds of the formula wherein X, Y, R1, R2, R3, R3, R4, and R5 are as described herein and enantiomers and pharmaceutically acceptable salts and esters thereof which are useful as anticancer agents.